Jacqui Shaw
A5066575183- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Cancer Cells and Metastasis
- Molecular Biology Techniques and Applications
- Lung Cancer Treatments and Mutations
- Gene expression and cancer classification
- Genomics and Chromatin Dynamics
- Lymphoma Diagnosis and Treatment
- Cancer-related gene regulation
- Breast Cancer Treatment Studies
- Cell Adhesion Molecules Research
- BRCA gene mutations in cancer
- Pancreatic and Hepatic Oncology Research
- DNA Repair Mechanisms
- Lung Cancer Research Studies
- Single-cell and spatial transcriptomics
- Advanced biosensing and bioanalysis techniques
- Cancer Immunotherapy and Biomarkers
- Epigenetics and DNA Methylation
- Genetic Neurodegenerative Diseases
- RNA modifications and cancer
- Protease and Inhibitor Mechanisms
- Estrogen and related hormone effects
- Genomic variations and chromosomal abnormalities
- Biosensors and Analytical Detection
University of Leicester
2016-2025
NIHR Leicester Biomedical Research Centre
2025
Leicester Royal Infirmary
2014-2024
University of Liverpool
2023-2024
Foundation Medicine (United States)
2023-2024
Australian Centre for Heart Health
2024
The Alfred Hospital
2024
Medical University of Vienna
2023-2024
Saint Joseph's University
2024
Emergency Medicine Foundation
2023
Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and genome evolution have been limited to small retrospective cohorts. We wanted prospectively investigate in relation clinical outcome determine the clonal nature of driver events evolutionary processes early-stage NSCLC.
Highlights•Anti-CTLA-4 of hIgG1 and hIgG2 isotypes promote depletion intra-tumoral Treg cells•hIgG2 antibodies mediate in vivo cells via CD32a•Anti-CTLA-4 with enhanced Fc effector function improves therapeutic outcomes•The CD16-V158F SNP is associated response to ipilimumab inflamed tumorsSummaryWith the use a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that equivalent tremelimumab regulatory T (Treg) cell vivo, increasing CD8+ ratio promoting tumor rejection....
One of the benefits Digital PCR (dPCR) is potential for unparalleled precision enabling smaller fold change measurements. An example an assessment that could benefit from such improved measurement tumour-associated copy number variation (CNV) in cell free DNA (cfDNA) fraction patient blood plasma. To investigate dPCR and compare it with established technique quantitative (qPCR), we used breast cancer lines to HER2 gene amplification modelled a range different CNVs. We showed that, equal...
Up to 30% of patients with breast cancer relapse after primary treatment. There are no sensitive and reliable tests monitor these detect distant metastases before overt recurrence. Here, we demonstrate the use personalized circulating tumor DNA (ctDNA) profiling for detection recurrence in cancer.
TRACERx, a prospective study of patients with primary non-small cell lung cancer, aims to map the genomic landscape cancer by tracking clonal heterogeneity and tumour evolution from diagnosis relapse.
The purpose of this study was to directly compare mutation profiles in multiple single circulating tumor cells (CTC) and cell-free DNA (cfDNA) isolated from the same blood samples taken patients with metastatic breast cancer (MBC). We aimed determine whether cfDNA would reflect heterogeneity observed 40 CTCs.
Lung cancer is the leading cause of cancer-associated mortality worldwide
Metastatic disease is responsible for the majority of cancer-related deaths
Abstract Intratumour heterogeneity (ITH) fuels lung cancer evolution, which leads to immune evasion and resistance therapy 1 . Here, using paired whole-exome RNA sequencing data, we investigate intratumour transcriptomic diversity in 354 non-small cell tumours from 347 out of the first 421 patients prospectively recruited into TRACERx study 2,3 Analyses 947 tumour regions, representing both primary metastatic disease, alongside 96 tumour-adjacent normal tissue samples implicate transcriptome...
Abstract Murine tissues harbor signature γδ T cell compartments with profound yet differential impacts on carcinogenesis. Conversely, human tissue-resident cells are less well defined. In the present study, we show that lung a resident Vδ1 population. Moreover, demonstrate memory and effector phenotypes were enriched in tumors compared nontumor tissues. Intratumoral possessed stem-like features skewed toward cytolysis helper type 1 function, akin to intratumoral natural killer CD8 +...
Biomarkers in breast cancer to monitor minimal residual disease have remained elusive. We hypothesized that genomic analysis of circulating free DNA (cfDNA) isolated from plasma may form the basis for a means detecting and monitoring cancer. profiled 251 genomes using Affymetrix SNP 6.0 arrays determine copy number variations (CNVs) loss heterozygosity (LOH), comparing 138 cfDNA samples with matched primary tumor normal leukocyte 65 patients eight healthy female controls. Concordance...
Circulating nucleic acids (CNAs) are under investigation as a liquid biopsy in cancer. However there is wide variation blood processing and methods for isolation of circulating free DNA (cfDNA) microRNAs (miRNAs). Here we compare the extraction efficiency reproducibility 4 commercially available kits cfDNA 3 miRNA using spike-in reference templates. We also effects increasing time between venepuncture centrifugation differential force on recovery CNAs. was quantified by TaqMan qPCR targeted...
Abstract BACKGROUND Activating mutations in the estrogen receptor 1 (ESR1) gene are acquired on treatment and can drive resistance to endocrine therapy. Because of spatial temporal limitations needle core biopsies, our goal was develop a highly sensitive, less invasive method detecting activating ESR1 via circulating cell-free DNA (cfDNA) tumor cells as “liquid biopsy.” METHODS We developed targeted 23-amplicon next-generation sequencing (NGS) panel for detection hot-spot ESR1,...
Breast cancer tissues are heterogeneous and show diverse somatic mutations copy number alterations (CNAs). We used a novel targeted next generation sequencing (NGS) panel to examine cell-free DNA (cfDNA) detect gene amplification in women with metastatic breast (MBC).
Abstract Background Breast cancer (BC) is the most common in women, and despite introduction of new screening programmes, therapies monitoring technologies, there still a need to develop more useful tests for treatment response inform clinical decision making. The purpose this study was compare circulating cell-free DNA (cfDNA) tumour cells (CTCs) with conventional breast blood biomarkers (CA15-3 alkaline phosphatase (AP)) as predictors prognosis patients metastatic (MBC). Methods One...